Asimov

Overview

Builds an end-to-end genetic design platform combining synthetic biology and computational tools for biologics, cell therapy, and gene therapy development.

Part of the Boston ecosystem

Related

• Boston Tech Week 2026Citywide unconference coordinating community-created events over seven days, with submission support, a shared calendar, and promotion that helps event hosts reach broader audiences.
• Convergent ResearchBuilds and operates focused research organizations that identify scientific bottlenecks, match funders with teams, and provide operational support for public research infrastructure.
• General CatalystInvests in portfolio companies and acquired a hospital system to test a model for more proactive, accessible, affordable healthcare for American patients.
• MassChallengeBoston-based equity-free accelerator with sector-specific tracks (HealthTech, FinTech, FrontierTech). Each cohort runs 4 months with a $0 equity model funded by sponsors and government partners.
• Merck Cambridge Discovery ($MRK)Develops medicines and vaccines through research, clinical trials, and publications, focusing on diseases including cancer, infectious, cardiometabolic, respiratory, immune, neurological, and eye conditions.
• MITProvides education, research, innovation, and public service to prepare learners, advance knowledge, and address needs of the nation and world.
• MIT delta vAccelerates startup teams by providing mentors, investor networks, partner office hours, workshops, and perks for builders developing ventures that need scaling support.
• Northpond VenturesBuilds and supports science- and technology-driven businesses, including point-of-care diagnostics, for innovators developing breakthroughs with human health applications and broader societal impact.
• OpenEvidenceSearches medical knowledge with AI. Also: Biotech.
• Pillar VCInvests at inception in technical founders pursuing breakthrough companies, and provides founder resources such as playlists, startup templates, events, and guides.
• Relay Therapeutics ($RLAY)Develops small molecule medicines using computational and experimental protein-motion analysis, targeting previously hard-to-drug precision medicine targets in oncology and genetic disease.
• Safar PartnersInvests in seed to growth-stage platform technology companies from academic research, supporting founders tackling major challenges in clean technology, materials, AI, robotics, life sciences, and medical devices.